["{\n\"step_by_step_thinking\": \"The question is asking about the type of clinical trial conducted to assess the antileukemic activity of a new tyrosine kinase inhibitor in patients with chronic myeloid leukemia in blast crisis. The study has patients enrolled and assigned to successive dose cohorts, and treatment efficacy is determined based on regular complete blood counts and bone marrow assessments. This suggests that the study is open-label, as the patients are informed about the treatment they will receive.\",\n\"answer_choice\": \"C\""]